|Delivery||Report Code||Available Format|
|24-72 Working Hours||LS10348|
The global peptide therapeutics market is growing significantly due to the increasing prevalence of cardiovascular diseases and cancer, advances in peptide therapeutics manufacturing technology, and increasing healthcare expenditure. In addition, growing research and development activities along with a rich peptide therapeutics pipeline is expected to support the growth of the peptide therapeutics market. Patent expiration of several peptide drugs in the coming years will create ample opportunities for the global generic peptide therapeutics market to grow at a significant rate in the forecasted period. Peptides are made up of short chains of amino acid monomers. Peptide therapeutics have applications in several indications such as cancer, central nervous system disorders, respiratory disorders, and cardiovascular diseases; this is due to high selectivity, efficacy and safety of peptides.
The advanced research and development facilities and new peptide developments by the pharmaceutical companies are propelling the demand for cost effective peptide therapeutics. However, production of peptides in a large scale with the increasing complexities of peptides is a major challenge for the global peptide therapeutics market. Development of multifunctional peptides and increasing number of collaboration for the development of peptide conjugates are trends in the global peptide therapeutics market.
Peptide therapeutics market can be categorized on the basis of marketing type, route of administration, application, and. Based on marketing type, the peptide therapeutics market can be categorized as generic peptides and branded peptides. On the basis of route of administration, peptide therapeutics market can be segmented as oral mode of administration and parenteral mode of administration.
In addition, based on applications, the market can be categorized as gastrointestinal disorders, infection, respiratory disorders, central nervous system, metabolic disorders, cardiovascular diseases, hematological disorders, acromegaly, cancer and others. Cancer leads the market due to increasing number of new cancer cases.
Some of the factors driving the growth of the global peptide therapeutics market are increasing prevalence of chronic diseases, increasing healthcare expenditure, and increasing investment by pharmaceutical companies for the development of peptide therapeutics. In addition, advancements in peptide manufacturing technology and rich peptide research and development pipeline are propelling the growth of the global peptide therapeutics market. However, stringent regulatory requirements for drug approval, high cost of peptide drugs, and chemical complexities and instability of peptides are some of the factors restraining the growth of the global peptide therapeutics market.
Geographically, North America will be leading the global peptide therapeutics market in the coming years due to high prevalence of chronic diseases, high healthcare expenditure, and high research and development activities. In addition, advancements in the peptide manufacturing technology and rich peptide therapeutics pipeline are fueling the growth of peptide therapeutics market in North America region. Asia-Pacific is the fastest growing region in the global peptide therapeutics market. The major reasons for the fastest growth in the region are growing research and development activities, increasing prevalence of cancer and cardiovascular diseases, and increasing healthcare expenditure. Moreover, the peptide therapeutics market is growing rapidly due to the high generic drug market potential in the emerging economies, such as India and China.
Some of the major players operating in the global peptide therapeutics market are, Sanofi, Teva Pharmaceutical Industries Ltd., Novartis AG, Ipsen S.A., AstraZeneca plc, Amgen Inc., Eli Lilly and Company, Lonza Group Ltd., Merck & Co. Inc., Novo Nordisk A/S, F. Hoffmann-La Roche AG, Bachem Holding AG, PolyPeptide Group, and CordenPharma International GmbH.